Aetna Is Changing Cancer Prior Authorization. Here’s What Oncology Practices Need to Know

If you run an oncology practice that sees Aetna patients, you already know the drill: diagnosis, then paperwork, then more paperwork, then — eventually — treatment. Aetna itself says its providers have been submitting an average of four separate prior authorizations per cancer patient. That’s about to change, and the change is worth understanding before it reaches your patients, not after.

What’s Actually Changing

On September 17, Aetna announced it’s expanding a bundled prior authorization model to cover all cancer types, replacing the current system of multiple separate approvals with a single upfront request covering a broader set of cancer treatments and related services. The bundle can combine medical oncology services, such as chemotherapy and immunotherapy, with radiation oncology services and associated high-tech imaging needs such as MRI or CT scans.

The rollout is happening in stages. For Medicaid members in eight states — Oklahoma, Illinois, Maryland, New Jersey, Virginia, Florida, Kentucky and West Virginia — the expanded bundles took effect September 1, for providers who use the Eviti portal to submit prior authorizations. Aetna says it plans to extend the model to its Medicare Advantage and commercial lines in the first half of 2027.

This isn’t a first attempt. Aetna piloted bundled authorizations last year for lung, breast and prostate cancer specifically, and the company says almost 25% of eligible members have had their prior authorizations bundled under that pilot. The September announcement scales that pilot to every cancer type and sets a timeline for expanding it beyond Medicaid.

What “Bundled” Actually Means for Your Workflow

The practical shift is in when the approval decision happens, not just how many forms you fill out. Instead of getting separate sign-off at each treatment milestone — imaging, then chemo, then a scan to check response, then the next line of therapy — the bundle is meant to authorize a broader set of treatments and services upfront, at the start of the care journey.

For a practice, that changes a few things worth planning for:

Front-loaded documentation may matter more. Because the initial request covers a broader set of services, practices may need to provide more complete documentation at the outset rather than building the authorization around a single immediate service. Practices used to submitting narrow, single-service justifications may need to rethink how comprehensive that first submission is.

Fewer authorization touchpoints doesn’t mean zero. Aetna has said oncologists retain the flexibility to make care decisions as treatment plans evolve, which suggests the bundle isn’t a blank check for the entire treatment course regardless of how the disease responds. What isn’t yet clear from Aetna’s public statements is exactly how changes to a treatment plan — a switch in regimen, an added line of therapy — get handled once the original bundle is in place. That’s a workflow detail practices in the eight rollout states will likely learn by doing over the next few months, and it’s worth asking your Aetna provider relations contact directly rather than assuming.

Revenue cycle timing may shift. Fewer authorization cycles generally means fewer points where a claim can stall waiting on approval — the upside providers have been asking insurers for. But it also means more is riding on that single upfront authorization being complete and accurate, since there are fewer subsequent checkpoints to catch a documentation gap.

Why This Is Happening Now

This fits into a broader pattern rather than a one-off move by Aetna. The HHS secured a pledge from major insurers last year to voluntarily streamline prior authorization, and participating insurers reported this spring that they’d cut 11% of preapprovals since making that commitment. UnitedHealthcare said earlier this month it’s eliminating prior authorization for roughly 1,700 medical codes starting this fall, part of a stated goal to cut 30% of its preapproval requirements by year’s end. Aetna has also expanded bundling to musculoskeletal conditions — X-rays, knee surgeries, certain medications — building on the same model it piloted in oncology.

That said, it’s worth reading these announcements with the same skepticism many physician groups already bring. Prior authorization denials are also frequently overturned on appeal, although overturn rates vary substantially by insurer and market — a KFF analysis found 67% of appealed standard denials were overturned in Medicare Advantage, versus 47% in Medicaid managed care and 43% in the ACA Marketplace. That history has contributed to skepticism among providers about whether changes in utilization management will meaningfully reduce administrative burden. The same KFF analysis, covering 14 insurers and roughly 71 million enrollees across 2025 data, found standard prior authorization denial rates of 12% in Medicare Advantage, 14% in Medicaid managed care and 18% in ACA Marketplace plans, with wide variation by insurer — CVS Health’s Medicare Advantage plans, for context, denied about 8% of standard requests. Bundling fewer requests doesn’t automatically mean easier approvals — it means fewer, higher-stakes approval decisions — and it remains to be seen how Aetna’s approval rates and turnaround times within the bundled model compare to the status quo once more data is available.

What to Do Between Now and the Full Rollout

If you’re in one of the eight Medicaid rollout states and use Eviti: this is already live. Confirm with your billing and prior authorization staff that they understand the bundled submission process, and flag any early friction points directly to Aetna — the company has said it’s still evaluating which additional states or conditions to expand to next, which means early feedback may actually shape the next phase.

If you’re not in a rollout state yet: you have several months before the planned expansion to Medicare Advantage and commercial lines begins in 2027. That’s a reasonable window to review how your practice currently structures initial cancer treatment documentation and whether it’s built for a single comprehensive submission versus a series of incremental ones.

Either way: don’t assume “bundled” means “fewer administrative staff hours” until you’ve seen it in practice at your own site. The theoretical benefit — less paperwork, fewer delays — is the stated goal, but the actual time savings will depend on how smoothly Aetna’s process handles treatment plan changes mid-course, which is the detail that determines whether this becomes a genuine burden reduction or just a different shape of the same burden.

Sources

Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain — KFF